Teva Pharmaceutical Industries (TEVA) Net Income towards Common Stockholders (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Net Income towards Common Stockholders for 18 consecutive years, with -$576.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Income towards Common Stockholders fell 304.98% year-over-year to -$576.0 million; the trailing twelve-month figure through Jun 2026 stood at $696.0 million (up 516.77% YoY), and the FY2025 full-year result was $1.4 billion, up 171.58% from the prior year.
• Net Income towards Common Stockholders declined to -$576.0 million in Q2 2026 per TEVA's latest filing, from $370.0 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $519.0 million in Q1 2024 and bottomed at -$1.3 billion in Q4 2022.
• Historically, Net Income towards Common Stockholders has averaged -$164.8 million across 5 years, with a median of -$94.5 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders tumbled 1286.59% in 2022, then soared 305.14% in 2024.
• Over 5 years, Net Income towards Common Stockholders stood at -$1.3 billion in 2022, then surged by 134.93% to $466.0 million in 2023, then slumped by 159.01% to -$275.0 million in 2024, then soared by 270.91% to $470.0 million in 2025, then sank by 222.55% to -$576.0 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$576.0 million, $370.0 million, and $470.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.